Inotuzumab ozogamicin in individuals with Down syndrome and acute lymphoblastic leukemia

This publication has 15 references indexed in Scilit:

• Reduced‐Intensity Chemotherapy With Immunotherapy for Children With Down Syndrome and B‐Cell Acute Lymphoblastic Leukemia
  Pediatric Blood & Cancer, 2025
• Hyper‐CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome‐Negative B‐Cell Acute Lymphoblastic Leukemia
  American Journal of Hematology, 2025
• Inotuzumab ozogamicin for relapse prevention in a boy with Down syndrome and relapsed acute lymphoblastic leukemia
  International Journal of Hematology, 2024
• Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia
  Clinical Lymphoma Myeloma and Leukemia, 2023
• Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
  The Lancet Haematology, 2023
• Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
  Leukemia, 2022
• Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
  Cancer, 2019
• Use of inotuzumab‐ozogamicin in a child with Down syndrome and refractory B‐cell precursor acute lymphoblastic leukemia
  Pediatric Blood & Cancer, 2018
• Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
  Leukemia, 2018
• Outcome of transplantation for acute lymphoblastic leukemia in children with down syndrome
  Pediatric Blood & Cancer, 2014